首页> 外文期刊>Experimental and clinical transplantation >Liver Transplant in Budd-Chiari Syndrome: A Single-center Experience in Saudi Arabia
【24h】

Liver Transplant in Budd-Chiari Syndrome: A Single-center Experience in Saudi Arabia

机译:Budd-Chiari综合征的肝移植:沙特阿拉伯的单中心经验。

获取原文
           

摘要

Objectives: If they do not respond to other treatments, patients with Budd-Chiari syndrome are potential candidates for a liver transplant. Timing for transplant is controversial; however, before other systems deteriorate, early intervention in relatively stable patient may improve the outcome and survival of these patients. Materials and Methods: Six patients (2 women and 4 men) had Budd-Chiari syndrome (1.2%) among 475 patients who had undergone a liver transplant at our center between 2001 and 2012. Imaging modalities including duplex ultrasound, abdominal computed tomography angiography, and hematologic evaluation were part of our routine diagnostic work-up. Although we perform mostly living-donor liver transplants, these patients received a liver transplant from a deceased donor, because there was not enough evidence to justify a living-donor liver transplant. We thought that not replacing the caval vein might negatively influence the outcome. Postoperatively, these recipients were started on a heparin infusion and triple therapy immunosuppression; only then was warfarin introduced as long-term anticoagulant. Results: Two patients died, 1 from uncontrollable bleeding and disseminated intravascular coagulopathy, and the other died in the intensive care unit after 5 months because of multiorgan failure and sepsis. One patient had portal vein thrombosis 9 months after the liver transplant; the other patient needed a liver retransplant after 5 years owing to liver failure, secondary to chronic rejection. Graft survival rate was 75%, and patient survival rate was 66.6%. Conclusions: This is the first article from Saudi Arabia to describe the outcome of a liver transplant in this subgroup of patients with Budd-Chiari syndrome. Treatment of Budd-Chiari syndrome follows a therapeutic algorithm that should start with anticoagulation and may end up with liver transplant; however, it should be considered early if other treatments fail.
机译:目的:如果他们对其他疗法无反应,则布加-基亚里综合征患者可能会进行肝移植。移植的时间是有争议的。但是,在其他系统恶化之前,对相对稳定的患者进行早期干预可能会改善这些患者的预后和生存率。资料与方法:2001年至2012年间,在我中心接受肝移植的475例患者中,有6例(2名女性和4名男性)患有Budd-Chiari综合征(占1.2%)。和血液学评估是我们常规诊断工作的一部分。尽管我们主要进行活体供肝移植,但由于没有足够的证据证明活体供肝移植是合理的,因此这些患者从已故的供体那里接受了肝移植。我们认为不更换腔静脉可能会对结果产生负面影响。术后,这些接受者开始接受肝素输注和三联疗法免疫抑制。直到那时,华法林才被引入作为长期抗凝剂。结果:2例患者死亡,1例由于无法控制的出血和弥散性血管内凝血病死亡,另一例在5个月后因多器官衰竭和败血症在重症监护病房死亡。肝移植后9个月,一名患者发生门静脉血栓;另一位患者由于肝功能衰竭(继发于慢性排斥反应)5年后需要进行肝脏移植。移植物存活率为75%,患者存活率为66.6%。结论:这是来自沙特阿拉伯的第一篇描述该Budd-Chiari综合征患者亚组肝移植结果的文章。 Budd-Chiari综合征的治疗遵循的治疗算法应从抗凝治疗开始,并可能以肝移植结束。但是,如果其他治疗失败,应及早考虑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号